- NeoHelix Regenerate, a precision peptide inspired by collagen‑hybridizing peptide (CHP) concepts, showed a 41% reduction in damaged collagen and a 65% increase in hyaluronic acid in a 56-day in vivo study of five women aged 60-70.
- SkinNexus Collag3n is a recombinant, human-identical Collagen III fragment produced by vegan yeast fermentation and developed with Bota Biosciences' SAION AI platform.
- In a 3D dermis model SkinNexus raised Collagen I by 48%, Collagen III by 82% and Collagen V by 71%, and in clinical tests on women aged 53-70 it improved tone and wrinkles within four weeks, outperforming a benchmark at ten times higher concentration.
- Both actives are being showcased at in-cosmetics Global in Paris and result from partnerships with 3Helix (NeoHelix) and Bota Biosciences (SkinNexus).
Overview
BASF introduced two cosmetic actives—NeoHelix Regenerate, a precision peptide drawing on collagen‑hybridizing peptide (CHP) concepts, and SkinNexus Collag3n, a recombinant bio‑identical Collagen III fragment produced by vegan yeast fermentation—intended to support collagen renewal and preservation; both will be showcased at in‑cosmetics Global in Paris.
NeoHelix Regenerate
NeoHelix is designed to enhance skin self‑repair and target damaged areas with high bioavailability; in a 56‑day in vivo study of five women aged 60–70 it reduced damaged collagen by 41% and increased hyaluronic acid by 65%, and separate assessments reported improvements in skin thickness, tonicity and forehead wrinkles versus a peptide benchmark.
SkinNexus Collag3n
SkinNexus is a recombinant, human‑identical Collagen III fragment developed via biotechnology and Bota Biosciences' SAION AI platform; in a 3D dermis model it raised Collagen I by 48%, Collagen III by 82% and Collagen V by 71%, and in clinical tests on women aged 53–70 it improved tone, sagging and fine lines within four weeks while outperforming a market benchmark at tenfold concentration.
Partnerships and manufacturing
NeoHelix was developed in collaboration with 3Helix adapting CHP concepts for personal care; SkinNexus’ discovery and scalable biomanufacturing were enabled through Bota Biosciences' AI‑driven experimental design and process optimization platform.
